Advertisement
Cryo-Cell has formalized agreements with C'elle distribution partners inthe United Kingdom, Ireland, Italy, Greece, Venezuela and Panama. Cryo-Cell'stechnology license partner, LifeCell Private Ltd., previously announced plansto introduce the C'elle service in India. C'elle has the potential to benefitmillions of women worldwide, since stem cells found in menstrual blood maypotentially be utilized in a broad range of future regenerative therapies topossibly treat a number of debilitating conditions such as heart disease,stroke and diabetes. C'elle stem cells may also have potential to be used incosmeceutical applications such as anti-aging and wound-healing.
Advertisement
"We are very excited to partner with Cryo-Cell International to distributeC'elle throughout Ireland and the UK," said Michael Doherty, ManagingDirector, Medicare Health & Living Ltd. "Cryo-Cell International is renownedfor its high standards and excellence. We believe that C'elle has thepotential to revolutionize women's health globally. This is truly a greatopportunity to bring an exclusive and innovative product to the women ofIreland and the UK enabling them to store their very own portfolio of stemcells."
Cryo-Cell continues to explore new global commercial and scientificpartnerships and recognizes that the regenerative potential of C'elle may oneday help to advance women's healthcare around the world. With theinternational launch of C'elle, Cryo-Cell's global partners will have a uniqueopportunity to expand their business models with a proprietary and highlydifferentiated service. Distribution of the C'elle service outside the UnitedStates may potentially create new sources of revenue for Cryo-Cell generatedfrom technology license and royalty fees, along with processing and storagerevenues for the service.
"We believe that the globalization of C'elle may generate significantworldwide awareness and interest in the potential of future stem celltherapeutic breakthroughs," said Mercedes Walton, Chairman and CEO ofCryo-Cell International. "We are pleased that our exclusive service, C'elle,will be introduced to women in different countries around the world. Thisexclusive and innovative service, based on Cryo-Cell's expansive intellectualproperty portfolio, provides women with the opportunity to store their ownstem cells for future potential therapeutic benefit."
"Clinical trials are now underway to test the safety and efficacy of stemcells found in menstrual blood (MenSCs) in animal models for diabetes,neurodegenerative and cardiovascular regenerative therapies," Waltoncontinued. "C'elle stem cells may one day be utilized in regenerativemedicine therapies to potentially treat a broad range of diseases such asstroke, Alzheimer's and Parkinson's that afflict millions worldwide."
Studies published in the April, 2008 issue of Cell Transplantationdemonstrated that MenSCs proliferate rapidly and have significant potential todevelop into multiple cell types. C'elle menstrual stem cells offer an easilyaccessible, non-controversial and renewable stem cell source, and thesefindings could mean that these cells have the future potential to treat a hostof diseases. For further information about C'elle visit th
